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ABSTRACT 
 
Objective: Guidelines for administering amino acids to critically ill children are largely based on 
uncontrolled observational studies and expert opinion, without support from rigorous outcome studies. 
Also, data on circulating amino acid concentrations during critical illness are scarce. We thoroughly 
studied the time profiles of circulating amino acid concentrations in critically ill children who received 
standard nutritional care according to international guidelines. 
Design: This is a subanalysis of pediatric critically ill patients included in a large  (n=700) randomized 
controlled study on intensive insulin therapy (IIT).  
Setting: The study was conducted at a university hospital pediatric intensive care unit (PICU). 
Patients: We studied 100 patients in PICU for at least 3 days following cardiac surgery. 
Interventions: Patients were assigned to IIT targeting normal-for-age fasting blood glucose 
concentrations or insulin infusion only to prevent excessive hyperglycemia. 
Measurements and Main Results: Plasma amino acid concentrations were measured upon 
admission, day 3 and day 7 in PICU. Upon admission, the concentrations of most amino acids were 
comparable to those reported for healthy children. Total amino acid concentrations remained stable 
during ICU stay, but individual amino acids showed different time profiles with 8 of them showing an 
increase and 5 a decrease. Non-surviving children had higher total amino acid concentrations and 
individual amino acids than survivors upon admission and/or during ICU stay. IIT lowered the 
concentrations of total amino acids and several individual amino acids. Neonates showed somewhat 
different amino acid profiles with rather increased concentrations from baseline with time in ICU for 
total amino acids and several individual amino acids as compared with older infants and children. 
Conclusions: Circulating amino acid concentrations in critically ill children after cardiac surgery 
differ according to survival status, blood glucose control with IIT and age.  
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INTRODUCTION 
 
In current practice, mixed essential and non-essential amino acids are added to parenteral 
nutrition for critically ill patients. However, composition and timing of administration are largely 
based on uncontrolled observational studies and expert opinion (1-5). In this regard, protein 
requirements and demand for amino acids are thought to be higher during critical illness (6, 7). After 
an acute insult, catabolic pathways are strongly activated (8). Muscle proteins then constitute the 
major source of amino acid release to support increased amino acid demand as substrate for de novo 
protein synthesis, the immune/inflammatory system and wound healing, amongst others (6-10). When 
this hypercatabolic state is sustained with prolonged critical illness, profound erosion of lean tissue 
mass ensues, which has been associated with severe weakness and prolonged convalescence. Rigorous 
data on the efficacy of various amino acid formulations with regard to clinical outcome and optimal 
timing are needed to more specifically guide amino acid dosing in critically ill patients to minimize 
lean tissue loss and/or optimize amino acid availability for other processes (5). Safety also needs to be 
considered as administration of too high doses may induce toxicity (11). For critically ill children in 
particular, data are insufficient to guide macronutrient intake by evidence-based recommendations (4, 
7). Whereas an aggressive early enteral nutrition protocol has shown to improve nitrogen balance in 
critically ill children (12), only limited data are available on plasma amino acid concentrations in this 
vulnerable patient population (13-15). 
We performed a large randomized controlled study on the maintenance of age-adjusted 
normoglycemia with intensive insulin therapy (IIT) in critically ill children, showing prevention of 
serious intensive care unit (ICU) morbidity and reduced ICU mortality (16). Although the intervention 
strongly increased the incidence of brief hypoglycemia episodes, it did not cause any detectable harm 
to intelligence and even improved other areas of cognition (17). This study offered us the opportunity 
to thoroughly analyze time profiles of circulating amino acid concentrations in critically ill children. 
For this purpose, we selected a subgroup of cardiac surgery patients, who also received standardized 
nutritional care according to international guidelines (18). We first assessed whether there was a 
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relation between individual amino acid concentrations and outcome, as such information could shed 
light on deficient or potentially toxic amino acid concentrations. Next, we studied the impact of IIT on 
the amino acid concentrations. Given that hyperglycemia promotes catabolism (19), that insulin is an 
anabolic hormone known to suppress amino acid release from muscle and to stimulate amino acid 
uptake (20), and that we previously demonstrated improved insulin sensitivity in skeletal muscle with 
IIT (21), we hypothesized that circulating amino acid concentrations would be lower in patients who 
received IIT. Finally, we evaluated whether the time profiles differed with age, as amino acid 
concentrations vary according to age in healthy children (22) and different nutritional 
recommendations are applied dependent on the critically ill patient’s age (18). 
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MATERIALS AND METHODS 
 
Patients 
We selected a subgroup of patients included in a large, prospective randomized controlled 
study on age-adjusted tight glycemic control with IIT in the pediatric ICU (PICU) (NCT00214916; 
Institutional Review Board approval number ML2586) (16). Written informed consent had been 
obtained from the patients’ next-of-kin. For exclusion criteria and CONSORT diagram of the 
randomized study, we refer to the original report (16).  
The patients had been randomly allocated to conventional insulin therapy (CIT) or IIT. CIT 
patients only received insulin when blood glucose concentrations exceeded 215 mg/dL (11.9 mmol/L) 
twice, and the insulin dose was adjusted to keep blood glucose between 180-215 mg/dL (10.0-11.9 
mmol/L). The insulin infusion was tapered down and stopped when the blood glucose concentration 
fell below 180 mg/dL (10.0 mmol/L). In the patients receiving IIT, insulin was continuously infused to 
control blood glucose concentrations within the age-adjusted normal fasting range of 50–80 mg/dL 
(2.8–4.4 mmol/L) for infants (<1 year) and 70–100 mg/dL (3.9–5.6 mmol/L) for children (1–16 years) 
(23). Insulin infusion was started when the blood glucose concentration exceeded the upper limit of 
normal and the dose was adjusted to maintain concentrations within the defined targets.  
For this subanalysis, we randomly selected 50 patients of the CIT group and 50 patients of the 
IIT group who were admitted to the PICU after major surgery for congenital heart defects and needed 
intensive care for at least 3 days (Fig. 1). In each group, we randomly selected 30 infants (of which 7-
8 neonates ≤ 4 weeks old) and 20 children. Furthermore, of the 50 patients in each group, 20 needed 
intensive care for at least 7 days. The patients were matched for age, BMI, gender, day 1 PEdiatric 
Logistic Organ Dysfunction (PELOD) score and Risk Adjustment in Congenital Heart Surgery 
(RACHS) score. These and other baseline characteristics are presented in Table 1 and Supplemental 
Digital Content Table 1. The children received (par)enteral nutrition according to the nutritional 
guidelines published by Shann et al. and described in detail in the original report (16, 18). Intake of 
individual amino acids and total caloric intake are described in Table 2.  
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 Biochemical analyses 
 Whole blood glucose concentrations were measured in arterial blood at 1-4 hour intervals 
(ABL700 blood gas analyzer, Radiometer Medical A/S, Copenhagen, Denmark). Arterial blood was 
systematically sampled upon admission (prior to initiation of feeding and glucose management) and 
daily at 6 a.m. during PICU stay. Plasma was kept frozen at -80°C until analysis.  
 Amino acid concentrations were quantified in plasma samples taken upon admission and on 
day 3 and day 7 in PICU. Plasma sample sets were incomplete for 2 patients. The amino acids 
analyzed included alanine, arginine, asparagine, glutamine, glutamate, glycine, histidine, isoleucine, 
leucine, lysine, methionine, phenylalanine, serine, taurine, threonine, tryptophan, tyrosine and valine. 
Before HPLC analysis, plasma samples were deproteinized on ice by addition of 3% sulfosalicylic 
acid that contained 0.2 mM L-norvaline as internal standard, followed by centrifugation at 600 g (20 
minutes at 4°C) and filtration of the supernatant through a 0.22 µm membrane filter. The amino acids 
were derivatized with ortho-phtaldialdehyde/3-mercaptopropionic acid and the HPLC analyses of free 
amino acids were performed as described previously using a Ymc-packODS-AQ 150 x 4.6 mm 
column on a Waters 600E system with Waters 717plus autosampler (Waters SverigeAB, Sollentuna, 
Sweden) and 821 FP Jasco fluorescence detector (Mölndal, Sweden, excitation at 340 nm and 
emission at 450 nm) (24). 
 
Statistical analysis 
Analyses were performed using Statview 5.0.1 (SAS Institute, Cary, NC). Differences 
between groups were assessed by Chi-square test (proportions), Student’s t-test (normally distributed 
data), and Mann-Whitney U test (not-normally distributed data). Main effects between groups were 
analyzed by repeated measures ANOVA. p≤0.05 was considered statistically significant. 
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RESULTS 
 
Natural time course of the amino acid concentrations during ICU stay 
We first compared amino acid concentrations in critically ill children upon ICU admission, 
prior to initiation of nutrition (Supplemental Digital Content Table 2), with those reported for different 
age groups (0-1, 1-4 and 5-15 years old) of healthy children in the post-absorptive state (22). The sum 
of all measured amino acids (total amino acids) appeared elevated upon admission. Concentrations of 
asparagine and tyrosine were lower, while concentrations of glutamate, lysine, methionine, 
phenylalanine and tryptophan were higher. The sum of branched-chain amino acids (BCAA) was also 
higher, although individual concentrations of isoleucine, leucine and valine were not clearly elevated.  
Amino acid measurements at baseline, day 3 and day 7 showed that concentrations of 
isoleucine, methionine, phenylalanine, serine, valine and essential amino acids (EAA) increased from 
baseline towards day 3, irrespective of length of stay, and returned to lower concentrations by day 7, 
except for methionine that increased further and serine and EAA that remained stable at elevated 
concentrations (Fig. 2). Arginine and threonine concentrations remained stable until day 3 and 
increased towards day 7, whereas glycine concentrations gradually increased towards day 3 and day 7. 
Concentrations of alanine, asparagine, glutamine, glutamate and taurine decreased by day 3. Except 
for a return to higher concentrations for glutamine, concentrations remained stable until day 7. 
Concentrations of histidine, leucine, lysine, tryptophan, tyrosine, total BCAA, and total amino acids 
did not change during ICU stay. Plasma concentrations of the individual amino acids in general did 
not systematically correlate with intake of the respective amino acids, except for glutamate (day 3: 
r2=0.117, p=0.0006: day 7: r2=0.193, p=0.005) and taurine (day 3: r2=0.134, p=0.0002: day 7: 
r2=0.242, p=0.001). 
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Amino acid concentrations in survivors versus non-survivors 
To gain insight in potential deficiency or toxicity of individual amino acid concentrations 
during critical illness, we compared their baseline concentrations and profiles in survivors and non-
survivors. In non-survivors, already upon ICU admission, several amino acids were higher than in 
survivors, including alanine (p<0.0001), glutamate (p=0.05), histidine (p=0.001), lysine (p=0.05), 
phenylalanine (p=0.02), and the sum of all measured amino acids (p=0.008) (Supplemental Digital 
Content Table 2). Time profiles could not be reliably compared for patients with an ICU stay shorter 
than 7 days (1 non-survivor versus 59 survivors). In patients who stayed in ICU for at least 7 days, the 
time course of amino acid concentrations from admission to day 7 overall was not affected by ICU 
survival state (Fig. 3). Only for leucine, different time profiles suggested an increase from baseline in 
the non-survivors and a decrease in survivors. Notwithstanding the absence of significant differences 
in the time profiles the concentrations of most amino acids were higher at day 3 and/or day 7 in non-
survivors than in survivors in univariable analysis (Supplemental Digital Content Table 2). Amino 
acid intake on day 3 and 7 in ICU was comparable in survivors and non-survivors (Table 2). 
 
Impact of intensive insulin therapy on amino acid concentrations 
To address our hypothesis that circulating amino acid concentrations would be lowered by 
strict blood glucose control with IIT, we compared their time profiles for the patients randomized to 
CIT versus IIT. Baseline amino acid concentrations were comparable for patients in the CIT and IIT 
groups, except for glycine (p=0.04), methionine (p=0.02) and threonine (p=0.04) for which the 
concentrations were higher in IIT patients (Supplemental Digital Content Table 2). IIT did not affect 
the time course of amino acid concentrations in patients who stayed less than 7 days in ICU, except for 
histidine, which had increased on day 3 compared to the admission value in IIT patients, while the 
concentration decreased in CIT patients (Fig. 4). In CIT patients who stayed in ICU for at least 7 days 
arginine, glutamate, lysine, threonine, BCAA, EAA, non-essential amino acids (not shown) and the 
sum of all amino acids increased, whereas this rise was suppressed by IIT. The concentrations of 
asparagine, glutamine and leucine did not change with time in the CIT group, but were lowered by 
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IIT. IIT had no clear effect on the other amino acids. Patients in the CIT and IIT groups had a 
comparable amino acid intake on day 3 and 7 in ICU (Table 2). 
 
Amino acid concentrations in neonates versus older infants and children 
 We addressed the impact of age on the amino acids by comparing their concentrations and 
profiles in neonates versus older infants and children. In neonates, admission concentrations of alanine 
(p=0.004), glycine (p<0.0001), methionine (p=0.04), serine (p=0.01) and threonine (p<0.0001) were 
higher, while admission concentrations of arginine (p=0.01) and glutamine (p=0.05) were lower as 
compared to older infants and children (Supplemental Digital Content Table 2). The time course of the 
amino acid concentrations did not differ between these age groups in patients with an ICU stay shorter 
than 7 days except for threonine, which decreased from admission to day 3 in neonates while there 
was no change in the older infants and children (Fig. 5). In neonates who stayed at least 7 days in ICU, 
concentrations of glutamate, leucine, valine and BCAA increased from admission to day 7, while these 
concentrations decreased in older infants and children. For isoleucine, the increase from admission to 
day 3 and the following decrease from day 3 to day 7 was more pronounced in neonates compared to 
older infants and children. Arginine, EAA and the sum of all amino acids increased from admission to 
day 7 in neonates, while there was no change in older infants and children. No significant differences 
were found for the other individual amino acids. The intake in ICU of most amino acids was higher in 
the neonates as compared with the older infants and children (Table 2). 
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DISCUSSION 
Recommendations for protein intake in critically ill children are largely based on 
observational studies and expert opinion, and circulating concentrations of amino acids have rarely 
been measured in such patients (1-5). More detailed information on amino acid concentrations in 
critically ill children is thus needed as a start to better guide amino acid administration in these 
patients. In the present exploratory analysis, we observed that the concentrations of most amino acids 
in critically ill children upon admission to the ICU were in the range of those reported for healthy 
children. While following the nutritional recommendations by expert guidelines for protein/amino acid 
requirements the concentrations of 8 amino acids increased, whereas 5 appeared to decrease during 
ICU stay, without effect on the total amino acid concentration. In non-survivors, the sum of all amino 
acids, as well as the concentrations of several individual amino acids, were higher during intensive 
care than in patients who would survive critical illness. Intensive insulin therapy lowered the 
concentrations of total amino acids and of 7 individual amino acids. Neonates showed somewhat 
different amino acid concentrations upon ICU admission and these concentrations rather increased 
from baseline for total and several individual amino acid concentrations during intensive care as 
compared with older infants and children. The impact of survival status, intensive insulin therapy and 
age was particularly present in patients who needed intensive care for at least 7 days. 
 It has been argued that amino acid requirement is increased during critical illness to meet an 
increased demand as substrate for protein synthesis, wound healing and the immune/inflammatory 
system, amongst others, while minimizing lean tissue loss (6, 7). Following internationally recognized 
guidelines for protein/amino acid administration to critically ill children (18), we observed that the 
concentrations of asparagine and tyrosine were low upon admission and remained low or even further 
decreased during ICU stay. Vice versa, glutamate, lysine, methionine, phenylalanine, tryptophan and 
BCAA were elevated upon ICU admission and remained high or even further increased during ICU 
stay. In addition, the patients developed subnormal concentrations of taurine and supranormal 
concentrations of glycine, serine and threonine with time in ICU as compared to the concentrations 
reported for healthy children (22). The observed decreases or increases theoretically may point to an 
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inadequately balanced composition of the adminstered amino acid formula, with some amino acids 
being too low in concentration (e.g. lack of asparagine and glutamine in the administered nutrition, as 
well as absent or low concentrations of taurine) and others too high for optimal use in vivo. However, 
circulating amino acid concentrations result from a complex balance between their consumption in 
different processes (e.g. protein synthesis, gluconeogenesis, synthesis of polyamines and nitric oxide) 
and entry into the plasma. The latter is not only determined by dietary intake, but also by de novo 
synthesis and release from protein breakdown. Thus, higher concentrations of amino acids also could 
be explained by increased protein breakdown, resulting from the hypercatabolic state of critical illness, 
which is insufficiently counteracted with feeding (25, 26).  
 We observed remarkable differences in amino acid concentrations according to survival status. 
Total amino acid concentrations and the concentrations of most individual amino acids were higher in 
non-survivors than in survivors, upon admission and/or during ICU stay. This could be explained by a 
more pronounced activation of catabolism in patients who would not survive, rather than a different 
amino acid intake, in line with hypercatabolism being an important risk factor for delayed recovery 
and death (26). Alternatively, the administered amino acid dose could have been excessive for these 
patients in particular, reaching a concentration of toxicity. Adverse effects have been reported for very 
high amino acid intake above 4 g/kg/day, including azotemia, metabolic acidosis, and 
neurodevelopmental abnormalities (7, 27), but are rarely seen with intakes of 2-3 g/kg/day (28). 
Nevertheless, toxicity may be reached at lower concentrations, particularly when renal and/or hepatic 
function of the children is severely compromised (7). In that regard, the immaturity of amino acid 
degradation pathways, nitrogen excretory function of the kidneys, and lack of small intestinal 
metabolism put parenterally fed neonates at risk of amino acid toxicity (29). Increases in several 
amino acids in critically ill neonates after surgery for necrotizing enterocolitis correlated with disease 
severity, mirrored the degree of liver dysfunction and disturbed amino acid metabolism in liver and 
muscle, and were more pronounced in non-survivors than in survivors (30). Interestingly, in fed adult 
prolonged critically ill patients, we recently observed an autophagy-deficiency phenotype, of which 
the severity correlated with the amount of infused amino acids (31). Furthermore, we observed that 
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giving parenteral nutrition to critically ill rabbits, especially when enriched in amino acids, suppressed 
autophagy (32). Autophagy serves a crucial cellular quality control function by clearance of damaged 
organelles and toxic large proteins and aggregates (33, 34). Fasting is its strongest physiological 
activator (35), whereas it is inhibited by feeding and particularly by amino acids (36). Excessive 
amino acids may thus compromise damage removal, which is required for recovery from organ failure 
and may as such increase the risk of death. 
We hypothesized that the amino acid concentrations in patients randomized to IIT would be 
lower than those in patients who received CIT. Several individual amino acids as well as total amino 
acid concentration were indeed lower in IIT patients, but only for the subgroup who needed intensive 
care for at least 7 days. According to the randomization, IIT patients had lower blood glucose and 
higher insulin concentrations than CIT patients, which both may have contributed to lowering of the 
amino acid concentrations. Hyperglycemia has been associated with an increased rate of muscle 
protein catabolism in severely burned patients (19). In critically ill rabbits maintained 
hyperinsulinemic, hyperglycemia activated ubiquitin-proteasome activity as compared with 
normoglycemia (37). Treatment of hyperglycemia in cancer patients following major surgery also 
improved skeletal muscle protein and amino acid metabolism (38). A study in severely injured patients 
showed direct stimulation of muscle protein synthesis by hyperinsulinemia (39). Improved insulin 
sensitivity in muscle when patients’ blood glucose concentrations are maintained normal during 
critical illness (21) may have played a role, as insulin resistance would interfere with the role of 
insulin as anabolic hormone that suppresses amino acid release from muscle while stimulating amino 
acid uptake (20). As amino acid concentrations on one hand are higher in non-survivors and on the 
other hand are lowered by IIT, this effect may have contributed to the better clinical outcome of the 
children who received this therapy (16). Effectively reaching age-adjusted normal fasting glycemia 
may be crucial to obtain clinical benefits as virtually unaltered circulating blood glucose in studies that 
targeted adult normal fasting ranges failed to convey clinical benefit (40, 41).  
Neonates had higher plasma concentrations of several amino acids upon admission and/or 
during ICU stay than older infants and children. This may in part be explained by a higher intake of 
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these amino acids according to the nutritional guidelines (7, 18), although a more severely activated 
catabolism cannot be excluded. Also in metabolically healthy children undergoing elective surgery an 
age-dependent distribution of plasma amino acid concentrations has been described, with 
characteristic patterns for individual amino acids (22, 42). A retrospective review that assessed intakes 
of parenteral amino acids for 116 critically ill children compared amino acid intake with breast milk 
amino acid content for infants, as golden standard, and with mixed muscle protein content in older 
children (4). This study showed that parenteral nutrition provided essential amino acids in higher 
amounts and non-essential amino acids in lower amounts than the recommended intake for healthy 
children and questioned the adequacy of the amounts of amino acids that are provided to critically ill 
children. As in that study, asparagine, glutamine and taurine intake was limited or absent in our study. 
This exploratory analysis has some inherent limitations. The random subgroup of patients was 
selected from within the group of cardiac surgery patients only, precluding extrapolation to other types 
of critical illness and potentially introducing bias as not all patients were studied. We did not 
simultaneously measure the amino acid concentrations in age-matched healthy children. Comparisons 
of upon-ICU admission concentrations with values in healthy children were based on healthy 
reference ranges in the literature (measured in venous blood using the same method) and not with an 
internal control population. Furthermore, we cannot exclude that pre-surgical amino acid 
concentrations were subnormal and raised to normal healthy concentrations in response to the severe 
surgical stress nor potential bias by administration of fresh frozen plasma during or shortly after 
surgery. We did not make any distinction between enteral and parenteral administration of the amino 
acids, but amount of enteral intake was mostly negligible as compared to the parenteral intake. Apart 
from the impact of randomized blood glucose control interventions, all other differences among the 
compared groups merely reflect association and not causality. No specific feeding intervention was 
tested, nor were patients selected for amino acid intake, but standardized nutritional guidelines were 
followed. Thus, we cannot make any statement about how much of the amino acids are actually 
needed, especially in light of the recent findings in the large randomized EPaNIC study showing faster 
recovery and fewer complications with late initiation of parenteral nutrition to complete enteral 
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nutrition as compared with early initiation (43). The observed differences in amino acid concentrations 
appear mostly not explained by respective intakes on the days of measurement, except for the 
observed association with age, as recommended amino acid intake is higher for neonates than for older 
children (7, 18). However, any impact of potential differences in pre-surgical nutritional intake cannot 
be excluded. 
 
CONCLUSIONS 
A nutritional strategy based on the recommendations by expert guidelines was associated with 
different responses in time of individual amino acids, with some of them increasing, whereas others 
decreased or remained stable. Higher concentrations of most amino acids were associated with 
mortality and strict glycemic control with IIT lowered concentrations of several individual amino 
acids and total amino acids. Higher, increasing concentrations in neonates as compared with older 
infants and children may be related to the higher recommended protein intake. Since amino acid 
profiles have rarely been measured in critically ill children, this large study (although mostly 
observational) provides important insight and, after confirmation in another observational study to 
avoid bias by chance, may serve as a basis for further nutritional intervention studies with fine-tuned 
amino acid compositions for critically ill children. 
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FIGURE LEGENDS 
 
Figure 1. CONSORT diagram 
The diagram shows how the 100 selected cardiac surgery patients are distributed in the general 
patient population included in the large randomized controlled study. To address the impact of at least 
a few days of critical illness and of the intervention, we confined our analyses to patients in ICU for at 
least 3 days (median ICU stay in the parent study), thus leaving available 163 and 127 patients in the 
CIT and IIT groups, respectively. To assess the impact of more prolonged critical illness, we studied a 
second time point, a priori set at 7 days in ICU. Of the 163 CIT patients remaining available for 
selection, 100 patients had an ICU stay between 3 and 6 days (61%) and 63 had an ICU stay of at least 
7 days (39%). Thus, we proportionally selected 30 patients (60%) with an ICU stay between 3 and 6 
days and 20 patients (40%) with an ICU stay of at least 7 days. In view of the higher proportion of 
infants among the patients remaining available, we withheld more infants (30 patients) than children 
(20 patients), randomly selected among the groups of interest. We maintained the same proportions 
with regard to ICU stay and age group to randomly select 50 patients from the IIT group. 
The selection included 10 non-survivors, 40 children > 1 year old and 60 infants of which 15 
neonates, for whom the distribution according to randomization and ICU length of stay is indicated. 
This is shown as the number of non-survivors, children, infants and neonates withheld in the selection, 
relative to the total number of non-survivors, children, infants and neonates in each final arm of the 
diagram. 
 
Figure 2. Natural time course of amino acid concentrations during intensive care  
Differences in amino acid concentrations over time were analyzed by repeated measures 
ANOVA. The line plots (means ± standard error of the mean) represent the changes in single amino 
acid concentrations, sum of branched chain amino acids (BCAA), sum of essential amino acids (EAA) 
and sum of all measured amino acids (total AA) on day 3 (d3) and day 7 (d7) versus the admission 
(adm) values. The means (circles, triangles) and standard error of the means (whiskers) are shown for 
40 patients with an ICU stay of at least 7 days (black circles) and 60 patients with an ICU stay of 
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minimum 3 but less than 7 days (grey triangles). P7d = within-subjects main effect of time for patients 
with an ICU stay of at least 7 days, P<7d = within-subjects main effect of time for patients with an ICU 
stay of minimum 3 but less than 7 days. 
 
Figure 3. The effect of survival or death on amino acid concentrations during intensive care  
Differences in amino acid concentrations between survivors and non-survivors and the 
evolution over time were analyzed by repeated measures ANOVA. The line plots (means ± standard 
error of the mean) represent the changes in single amino acid concentrations, sum of branched chain 
amino acids (BCAA), sum of essential amino acids (EAA)  and sum of all measured amino acids (total 
AA) on day 3 (d3) and day 7 (d7) versus the admission (adm) values. The means (circles, triangles) 
and standard error of the means (whiskers) are shown for 40 patients with an ICU stay of at least 7 
days (31 ICU survivors, open black circles; 9 ICU death, open grey triangles). Since only one of the 
60 patients with an ICU stay of minimum 3 but less than 7 days died in ICU, we did not include these 
patients in the graphs. P7d = p for patients with an ICU stay of at least 7 days; M = between-subjects 
main effect of mortality; T = within-subjects main effect of time; I = between-subjects by within-
subjects interaction of mortality by time. 
 
Figure 4. The effect of intensive insulin therapy on amino acid concentrations during intensive 
care 
Differences in amino acid concentrations between patients with intensive insulin therapy (IIT) 
and conventional therapy (CIT) and the evolution over time were analyzed by repeated measures 
ANOVA. The line plots (means ± standard error of the mean) represent the changes in single amino 
acid concentrations, sum of branched chain amino acids (BCAA), sum of essential amino acids (EAA)  
and sum of all measured amino acids (total AA) on day 3 (d3) and day 7 (d7) versus the admission 
(adm) values. The means (circles, triangles) and standard error of the means (whiskers) are shown for 
40 patients with an ICU stay of at least 7 days (20 CIT, black circles; 20 ITT, grey circles) and 60 
patients with an ICU stay of minimum 3 but less than 7 days (30 CIT, black triangles; 30 IIT, grey 
triangles). P7d = p for patients with an ICU stay of at least 7 days; P<7d = p for patients with an ICU 
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stay of minimum 3 but less than 7 days; R = between-subjects main effect of therapy (randomization); 
T = within-subjects main effect of time; I = between-subjects by within-subjects interaction of therapy 
by time. 
 
Figure 5. The effect of age on amino acid concentrations during intensive care: neonates versus 
older infants and children 
Differences in amino acid concentrations between neonates and the group of older infants and 
children and the evolution over time were analyzed by repeated measures ANOVA. The line plots 
(means ± standard error of the mean) represent the changes in single amino acid concentrations, sum 
of branched chain amino acids (BCAA), sum of essential amino acids (EAA)  and sum of all amino 
acids (total AA) on day 3 (d3) and day 7 (d7) versus the admission (adm) values. The means (circles, 
triangles) and standard error of the means (whiskers) are shown for 40 patients with an ICU stay of at 
least 7 days (30 no neonates, black circles; 10 neonates, grey circles) and 60 patients with an ICU stay 
of minimum 3 but less than 7 days (55 no neonates, black triangles; 5 neonates, grey triangles). P7d = p 
for patients with an ICU stay of at least 7 days; P<7d = p for patients with an ICU stay of minimum 3 
but less than 7 days; N = between-subjects main effect of age (yes or no neonate); T = within-subjects 
main effect of time; I = between-subjects by within-subjects interaction of age by time. 
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Table 1: Baseline characteristics, treatments in ICU and outcome of the patients 
 Conventional 
insulin therapy 
(n=50) 
Intensive 
insulin therapy  
(n=50) 
 
p 
    
Baseline characteristics    
Infant (age < 1 year) (no., %) 30 (60.0) 30 (60.0) >0.9 
Neonate (age < 4 weeks) (no., %) 8 (16.0) 7 (14.0) 0.8 
Weight (kg) (median – IQR) 6.4 (4.2–10.0) 5.7 (3.9–12.0) 0.7 
BMI (mean ± SD) 14.8 ± 2.5 14.8 ± 2.3 >0.9 
Gender (no., % male) 30 (60.0) 30 (60.0) >0.9 
Pre-randomization syndrome (no., %) 20 (40.0) 21 (42.0) 0.8 
RACHS score (median – IQR) 3 (2–3) 3 (2–3) 0.7 
Mechanical ventilation (no., %) 50 (100) 50 (100) >0.9 
ECMO or other assist device upon admission (no, %) 3 (6.0) 3 (6.0) >0.9 
Inotrope score for first 24 hrs (median – IQR) 2 (1–3) 2 (1–3) 0.2 
Inotrope score for first 24 hrs > 2 (no., %) 17 (34.0) 13 (26) 0.4 
Blood glucose upon admission (mg/dL) (mean ± SD) 163.4 ± 67.1 161.7 ± 77.5 0.9 
PELOD (first 24 h) (median – IQR) 12 (11–12) 12 (11–12) 0.5 
CRP (mg/L) (median – IQR) 23.8 (15.3–51.1) 22.8 (14.8–32.7) 0.4 
    
ICU length of stay and mortality    
ICU stay (days) (median – IQR) 5 (4–9) 5 (4–8) 0.9 
ICU mortality (no., %) 6 (12%) 4 (8%) 0.5 
Suspected or documented infection (no., %) 28 (56.0) 22 (44.0) 0.2 
Temperature ≤36°C or ≥38°C (no., %) 44 (88.0) 45 (90.0) 0.7 
Treated with inotropic drugs (no., %) 48 (96.0) 45 (90.0) 0.2 
   Days on inotropic drugs (median – IQR) 4 (3–7) 4 (2–7) 0.4 
Treated with corticosteroids (no., %) 15 (30.0) 10 (20.0) 0.2 
   Days on corticosteroids (median – IQR) 0 (0–1) 0 (0–0) 0.4 
Treated with NMBAs (no., %) 20 (40.0) 19 (38.0) 0.8 
   Days on NMBAs (median – IQR) 0 (0–1) 0 (0–1) 0.9 
Treated with sedatives (no., %) 50 (100.0) 48 (96.0) 0.2 
Glucose management    
   Mean morning blood glucose (mg/dL) (mean ± SD) 123.0 ± 21.3 89.9 ± 16.3 <0.0001 
   Maximal blood glucose (mean ± SD) 305.1 ± 186.5 252.0 ± 118.2 0.09 
   Treated with insulin (no., %) 24 (48.0) 50 (100.0) <0.0001 
   Mean daily insulin dose (IU/kg/day) (median – IQR) 0.00 (0.00–0.59) 1.21 (0.92–1.65) <0.0001 
   Hypoglycemia (no., %) 1 (2.0) 24 (48) <0.0001 
   Minimal blood glucose (mg/dL) (mean ± SD) 80.3 ± 20.0 42.3 ± 12.0 <0.0001 
 
RACHS: risk adjustment in congenital heart surgery score; ECMO: extracorporeal membrane 
oxygenation; PELOD: pediatric logistic organ dysfunction score; CRP: C-reactive protein; NMBAs: 
neuromuscular blocking agents. To convert glucose to mmol/L multiply by 0.05551. 
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Table 2: Amino acid and total caloric intake during intensive care unit stay 
Amino acid Day in ICU    All data   Survivors Non-survivors Age ≤ 4 weeks Age > 4 weeks        CIT        IIT 
    mg/kg Day 3      n=100       n=90         n=10         n=15         n=85       n=50       n=50 
 Day 7      n=40       n=31         n=9         n=10         n=30       n=20       n=20 
Alanine Day 3 78 (65-97) 76 (65-97) 86 (78-102) 106 (88-128) 72 (63-91)       a 81 (66-100) 78 (65-92) 
 Day 7 153 (77-205) 152 (66-223) 171 (127-195) 171 (132-181) 136 (59-224) 137 (65-192) 169 (87-210) 
Arginine Day 3 86 (71-103) 82 (70-103) 91 (85-105) 112 (91-130) 77 (69-98) a 85 (70-105) 86 (71-101) 
 Day 7 107 (80-131) 102 (79-150) 111 (82-127) 112 (91-117) 102 (71-156) 101 (75-128) 120 (87-142) 
Asparagine Day 3 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
 Day 7 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Aspartic acid Day 3 106 (88-125) 103 (88-124) 113 (85-129) 126 (113-148) 98 (86-118)     a 109 (87-129) 104 (88-122) 
 Day 7 91 (55-116) 87 (51-109) 111 (82-127) 112 (93-117) 83 (48-102) 86 (51-106) 97 (60-125) 
Cysteine  Day 3 34 (30-43) 34 (30-43) 37 (29-41) 43 (32-51) 33 (29-41)       a 35 (30-45) 34 (29-42) 
 Day 7 26 (12-31)  25 (11-32) 27 (20-31) 28 (23-31) 21 (10-31) 23 (13-32) 27 (12-31) 
Glutamine Day 3 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
 Day 7 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
Glutamate Day 3 223 (192-265) 216 (192-267) 236 (187-262) 276 (219-325) 214 (189-257) a 224 (190-267) 216 (192-258) 
 Day 7 170 (103-212) 169 (98-205) 193 (143-220) 193 (161-213) 159 (84-212) 166 (98-193)  173 (103-221) 
Glycine Day 3 54 (45-65) 53 (45-65) 58 (44-66) 67 (58-82) 50 (44-63)       a 56 (44-66)  54 (45-63) 
 Day 7 60 (46-80) 60 (50-110) 57 (42-65) 58 (48-60) 63 (45-110) 57 (42-75) 62 (53-95) 
Histidine Day 3 60 (51-74) 58 (51-75) 65 (50-70) 76 (64-94) 57 (50-69)       a 60 (50-75) 60 (52-72) 
 Day 7 61 (47-84) 62 (51-94) 57 (42-65) 59 (48-63) 65 (47-94) 57 (45-74) 65 (52-94) 
Isoleucine Day 3 97 (83-122) 94 (84-124) 102 (81-113) 124 (102-152) 93 (82-113)     a 97 (82-125) 97 (84-118) 
 Day 7 87 (72-102) 88 (75-114) 84 (62-96) 87 (70-96)  87 (73-116) 81 (67-100) 94 (77-103) 
Leucine Day 3 138 (115-172) 137 (114-172) 148 (138-168) 180 (147-212) 127 (111-160) a 143 (116-174) 137 (114-162) 
 Day 7 161 (110-210) 147 (105-205) 190 (141-216) 191 (147-210) 139 (100-209) 153 (107-204) 169 (115-213) 
Lysine Day 3 101 (85-126) 101 (84-127) 112 (101-124) 132 (114-161) 94 (82-118)     a 107 (85-128) 101 (84-120) 
 Day 7 143 (90-173) 139 (79-171) 152 (113-173) 152 (117-168) 138 (73-176) 131 (84-163) 159 (98-173) 
Methionine Day 3 46 (40-58) 46 (40-59) 50 (39-55)  60 (50-74) 45 (40-55)       a 46 (39-60) 47 (41-57) 
 Day 7 40 (34-71) 45 (36-77) 35 (26-40)       a 36 (30-40) 44 (36-77) 39 (28-66) 40 (38-77) 
Phenylalanine Day 3 132 (115-168) 132 (116-168) 144 (112-160) 175 (144-215) 130 (113-158) a 132 (110-169) 137 (117-166) 
 Day 7 85 (66-139) 109 (70-148) 73 (54-83)       a 75 (61-83) 108 (67-145) 78 (63-124) 94 (76-142) 
Proline Day 3 194 (170-246) 194 (170-247) 212 (168-235) 248 (212-292) 191 (169-234) a 194 (168-253) 202 (173-244) 
 Day 7 152 (102-178) 153 (101-188) 152 (113-173) 157 (127-168) 146 (96-189) 143 (100-184) 156 (120-175) 
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Amino acid Day in ICU    All data   Survivors Non-survivors Age ≤ 4 weeks Age > 4 weeks        CIT        IIT 
     mg/kg Day 3      n=100       n=90         n=10         n=15         n=85       n=50       n=50 
 Day 7      n=40       n=31         n=9         n=10         n=30       n=20       n=20 
Serine Day 3 180 (156-225) 180 (157-227) 196 (153-218) 230 (170-271) 177 (153-215) a 180 (145-229) 180 (160-215) 
 Day 7 104 (79-136)  105 (79-154) 103 (76-118) 106 (86-115) 100 (68-146) 98 (68-137) 111 (84-136) 
Taurine Day 3 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 
 Day 7 0 (0-7) 0 (0-2) 8 (6-9)             a 8 (6-9) 0 (0-1)             a 0 (0-7) 0 (0-8) 
Threonine Day 3 78 (65-97) 75 (64-97) 83 (75-95) 102 (83-117) 72 (63-90)       a 79 (66-98) 78 (65-92) 
 Day 7 94 (66-111) 90 (61-111) 98 (72-113) 98 (82-108) 88 (56-113) 83 (61-112)  100 (72-111) 
Tryptophan Day 3 26 (22-32) 25 (21-32) 29 (26-32) 34 (29-41) 24 (21-30)       a 27 (22-33) 26 (22-31) 
 Day 7 34 (23-40) 34 (21-39) 38 (28-43) 38 (29-41) 33 (20-39) 30 (22-38) 35 (24-42) 
Tyrosine Day 3 13 (11-16) 13 (11-16) 14 (10-16) 15 (13-18) 12 (11-16) 14 (11-17) 12 (11-15) 
 Day 7 12 (5-16) 12 (5-17) 14 (10-15) 14 (11-15) 10 (5-16) 12 (8-16) 13 (5-16) 
Valine Day 3 108 (92-135) 107 (92-137) 113 (89-125) 137 (113-168) 102 (90-124)   a 108 (91-137) 107 (93-130) 
 Day 7 102 (81-125) 102 (85-138) 98 (72-111) 101 (82-110) 102 (81-141) 98 (71-116) 109 (92-128) 
Total AAb Day 3 1.8 (1.5-2.2) 1.8 (1.5-2.2) 1.9 (1.5-2.0) 2.2 (1.9-2.7) 1.7 (1.5-2.0)      a 1.8 (1.5-2.3) 1.8 (1.5-2.1) 
 Day 7 1.8 (1.4-2.0) 1.8 (1.4-2.2) 1.8 (1.3-2.0) 1.8 (1.5-2.0) 1.7 (1.3-2.3) 1.6 (1.3-2.1) 2.0 (1.7-2.0) 
Total caloriesc Day 3 40 (32-51) 39 (32-51) 43 (38-49) 49 (43-57) 38 (30-48)       a 42 (33-50) 38 (31-51) 
 Day 7 70 (53-77) 69 (46-78) 70 (61-77) 75 (70-79) 65 (38-76)           a 68 (54-75) 72 (48-78) 
 
CIT: conventional insulin therapy, IIT: intensive insulin therapy, total AA: total amino acid intake.  a p ≤ 0.05 in unpaired t-test or Mann-Whitney U on the 
respective day for survivors versus non-survivors, neonates versus children older than 4 weeks, or CIT versus IIT. b Total protein intake in g/kg. Amino acid-
containing formulations for parenteral administration included Vamin18, Vamin-glucose and Vaminolact (administered to 1%, 87% and 4% of the patients on 
day 3 and to 25%, 33% and 38% on day 7). Enteral amino acids were provided via the patient’s home milk formula, including breast milk, Aptamil 1, Nan 1, 
Nan 2, Nutrilon 1, Nutrilon 2, Nutrilon 3, Nutrilon premium, Nutrilon soy, Neocate, Nutramigen, Omneo 2 and Pediasure. c Total caloric intake in kcal/kg; 
combination of enteral and parenteral nutrition;  on day 3 and day 7 at least partial enteral nutrition was tolerated in 28% and 38% of the patients, respectively. 
In most of the patients, the amino acids were administered exclusively by parenteral nutrition. Fourteen (day 3) and 12 (day 7) patients also received amino 
 2 
acids via the enteral route but in low amounts as compared to the amino acids administered parenterally. Amino acid intake was missing for 1 patient 
(survivor, no neonate, CIT patient). 
 3 





Supplemental Digital Content Table 1: Baseline characteristics, treatment in ICU and 
outcome of the patients  
 
Cardiac surgery intervention n  
Aortic arch reconstruction, with or without closure of ventricular septum defect 2 
Assist devices for acute heart failure due to myocarditis or other cardiomyopathy 3 
Closure aortopulmonary window 1 
Closure of ventricular rupture 1 
Coarctectomy 3 
Correction double outlet right ventricle 1 
Correction of valvular or subvalvular stenosis of the aortic valve 4 
Correction of valvular or subvalvular stenosis of the aortic valve and mitral valvuloplasty 1 
Correction one or more septum defects 
     inclusive atrial septum defect, ventricular septum defect and atrioventricular canal  
     defect, with or without banding/debanding/valvular vitia/reconstruction aortic arch 
29 
Correction tetralogy of Fallot 
     simple or with major aortopulmonary collateral arteries, first surgery or redo 
14 
Correction total anomalous pulmonary venous return 5 
Correction transposition of the great arteries 
     arterial switch with or without correction septum defect 
6 
  
Damus-Kaye-Stensel Norwood with placement ECMO 1 
Fontan/Glenn circuits 
    simple or with correction of other congenital anomalies, first surgery or redo 
18 
Mitral valvuloplasty 1 
Modified Blalock-Taussig shunt 1 
Norwood surgery and Fontan/Glenn circuits 1 
Norwood surgery 1 
Pulmonary artery banding 3 
Rastelli or Nikaidoh 3 
Right ventricular outflow tract reconstruction 1 
 
ECMO: Extracorporeal membrane oxygenation. 
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Supplemental Digital Content Table 2: Amino acid concentrations during intensive care unit stay 
Amino acid Day in ICU        All data       Survivors   Non-survivors Age ≤ 4 weeks   Age > 4 weeks       CIT       IIT 
   µmol/L Day 3         n=100           n=90           n=10          n=15          n=85       n=50       n=50 
 Day 7         n=40           n=31           n=9          n=10          n=30       n=20       n=20 
Alanine Admission   248 ± 101   234 ± 74   376 ± 194   a   315 ± 118   236 ± 93   a   243 ± 98   253 ± 105 
 Day 3   205 ± 102   194 ± 79   300 ± 200   a   243 ± 149   198 ± 90   216 ±122   194 ± 79 
 Day 7   237 ± 106   207 ± 73   339 ± 140   a   325 ± 108   207 ± 89   a   237 ±115   236 ± 99 
Arginine Admission     45 ± 17      45 ± 16     44 ± 23     35 ± 14     47 ± 17   a     43 ±17     47 ± 17 
 Day 3     44 ± 15     44 ± 15     43 ± 14     44 ± 13     43 ± 16     43 ± 13     44 ± 17 
 Day 7     54 ± 20     51 ± 21     64 ± 16     66 ± 21     50 ± 19   a     55 ± 20     53 ± 21 
Asparagine Admission     29 ± 10     29 ± 10     31 ± 13     26 ± 8     30 ± 11     28 ± 10     30 ± 11 
 Day 3     25 ± 12     24 ± 11     33 ± 17     a     25 ± 15     25 ± 12     25 ± 12     25 ± 13 
 Day 7     26 ± 11     24 ± 9     33 ± 14     a     29 ± 15     25 ± 9     28 ± 12     24 ± 9 
Glutamine Admission   397 ± 114   396 ± 115   410 ± 110   344 ± 107   407 ± 113 a   396 ± 121   399 ± 108 
 Day 3   351 ± 99   347 ± 98   383 ± 110   330 ± 102   354 ± 99   355 ± 87   346 ± 110 
 Day 7   368 ± 111   346 ± 95   441 ± 135   a   402 ± 145   356 ± 97   385 ± 100   351 ± 121 
Glutamate Admission   139 ± 74   134 ± 68   182 ± 108   a   130 ± 43   141 ± 78   142 ± 80   135 ± 68 
 Day 3   126 ± 53   122 ± 49   167 ± 70     a   168 ± 55   118 ± 49   a    141 ± 56   113 ± 45 a 
 Day 7   140 ± 56   133 ± 56   162 ± 52   179 ± 40   127 ± 55   a   162 ± 63   118 ± 38 a 
Glycine Admission   208 ± 75   205 ± 70   231 ± 113   276 ± 90   195 ± 66   a   192 ± 55   223 ± 89   a 
 Day 3   229 ± 87   219 ± 73   316 ± 143   a   291 ± 106   218 ± 79   a    230 ± 100   228 ± 73 
 Day 7   302 ± 128   279 ± 104   380 ± 175   a   370 ± 120   279 ± 124 a   297 ± 126   306 ± 133 
Histidine Admission     75 ± 34     71 ± 17   108 ± 93     a     73 ± 21     75 ± 36     76 ± 45     74 ± 20 
 Day 3     73 ± 23     71 ± 20     96 ± 33     a     80 ± 26     72 ± 22     71 ± 24     76 ± 22 
 Day 7     70 ± 23     65 ± 24     84 ± 15     a     71 ± 15     69 ± 25     68 ± 23     71 ± 24 
Isoleucine Admission     51 ± 20     50 ± 19     53 ± 27     42 ±16     52 ± 20     49 ± 17     52 ± 22 
 Day 3     62 ± 19     61 ± 18     74 ± 21     a     71 ± 25     61 ± 17     62 ± 19     63 ± 19 
 Day 7     53 ± 15     53 ± 16     55 ± 15     49 ± 15     54 ± 15     53 ± 17     53 ± 14 
Leucine Admission   107 ± 38   107 ± 36   111 ± 52     94 ± 34   109 ± 38   105 ± 28   109 ± 46 
 Day 3     99 ± 31     97 ± 26   121 ± 55     a   117 ± 49     96 ± 25   a   103 ± 36     96 ± 24 
 Day 7     98 ± 37     87 ± 25   135 ± 48     a   132 ± 51     86 ± 21   a   103 ± 46     93 ± 24 
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Amino acid Day in ICU        All data       Survivors   Non-survivors Age ≤ 4 weeks   Age > 4 weeks       CIT       IIT 
  µmol/L Day 3         n=100           n=90           n=10          n=15          n=85       n=50       n=50 
 Day 7         n=40           n=31           n=9          n=10          n=30       n=20       n=20 
Lysine Admission   162 ± 97   153 ± 84   241 ± 159   a   171 ± 88   160 ± 99   153 ± 92   171 ± 101 
 Day 3   177 ± 126   167 ± 96   266 ± 265   198 ± 216   173 ± 102   177 ± 145   177 ± 105 
 Day 7   193 ± 134   175 ± 115   254 ± 180   a   255 ± 174   172 ± 114 a   197 ± 163   189 ± 102 
Methionine Admission     22 ± 10     21 ± 9     27 ± 15     27 ± 10     21 ± 9     a     20 ± 7     24 ± 11   a 
 Day 3     30 ± 13     29 ± 12     38 ± 19     a     34 ±17     29 ± 12     29 ± 13     31 ± 13 
 Day 7     32 ± 14     32 ± 15     33 ± 10     29 ± 8     33 ± 16     30 ± 11     34 ± 17 
Phenylalanine Admission     70 ± 24     68 ± 21     86 ± 37     a     80 ± 29     68 ± 22     66 ± 21     74 ± 26 
 Day 3     99 ± 36     97 ± 31   120 ± 67     a   116 ± 58     96 ± 30   a     97 ± 38   101 ± 35 
 Day 7     82 ± 32     82 ± 34     85 ± 21     72 ± 25     86 ± 33     80 ± 24     85 ± 38 
Serine Admission   124 ± 40   122 ± 39   137 ± 49   147 ± 49   120 ± 37   a   120 ± 36   128 ± 44 
 Day 3   159 ± 53   157 ± 52   175 ± 59   188 ± 53   153 ± 52   a   162 ± 55   156 ± 52 
 Day 7   155 ± 46   149 ± 39   175 ± 65   174 ± 44   149 ± 46   154 ± 50   156 ± 44 
Taurine Admission     66 ± 30     65 ± 29     76 ± 35     67 ± 32     66 ± 30     67 ± 33     65 ± 29 
 Day 3     42 ± 30     41 ± 24     49 ± 62     39 ± 20     42 ± 31     46 ± 36     38 ± 23 
 Day 7     43 ± 25     39 ± 19     56 ± 37     58 ± 40     38 ± 14     44 ± 27     41 ± 22 
Threonine Admission   107 ± 67   105 ± 68   130 ± 51   170 ± 115     96 ± 47   a     93 ± 31   121 ± 87   a 
 Day 3   109 ± 42   105 ± 39   139 ± 58     a   145 ± 57   102 ± 35   a   112 ± 48   106 ± 36 
 Day 7   145 ± 65   131 ± 50   196 ± 87     a   194 ± 78   129 ± 53   a   148 ± 62   143 ±70 
Tryptophan Admission     32 ± 13     32 ± 12     34 ± 19     28 ± 9     33 ± 13     32 ± 14     33 ± 12 
 Day 3     32 ± 15     33 ± 15     29 ± 11     31 ± 10     33 ± 16     31 ± 12     33 ± 17 
 Day 7     31 ± 23     30 ± 24     35 ± 18     30 ± 13     31 ± 26     25 ± 13     37 ± 29 
Tyrosine Admission     13 ± 5     13 ± 5     16 ± 7     13 ± 7     13 ± 5     13 ± 5     14 ± 6 
 Day 3     13 ± 7     12 ± 6     20 ± 13     a     14 ± 7     13 ± 7     14 ± 7     13 ± 8 
 Day 7     13 ± 6     12 ± 6     16 ± 6       a     15 ± 4     12 ± 6     13 ± 6     13 ± 6 
Valine Admission   185 ± 54   184 ± 50   194 ± 85   171 ± 47   187 ± 56   181 ± 38   188 ± 67 
 Day 3   206 ± 57   203 ± 49   239 ± 100   a   237 ± 90   201 ± 47   a   206 ± 65   207 ± 48 
 Day 7   182 ± 55   173 ± 47   212 ± 74   202 ± 78   176 ± 45   188 ± 69   177 ± 38 
BCAA Admission   342 ± 107   341 ± 101   357 ± 159   307 ± 89   349 ± 110   336 ± 78   349 ± 130 
 Day 3   368 ± 102   360 ± 90   435 ± 172   a   425 ± 159   358 ± 86   a   371 ± 117   365 ± 88 
 Day 7   333 ± 93   313 ± 75   401 ± 120   a   383 ± 128   316 ± 73   a   344 ± 119   322 ± 58 
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Amino acid Day in ICU        All data       Survivors   Non-survivors Age ≤ 4 weeks   Age > 4 weeks       CIT       IIT 
  µmol/L Day 3         n=100           n=90           n=10          n=15          n=85       n=50       n=50 
 Day 7         n=40           n=31           n=9          n=10          n=30       n=20       n=20 
EAA Admission 811 ± 245 792 ± 217 984 ± 394 855 ± 287 803 ± 238 775 ± 199 848 ± 282 
 Day 3 891 ± 289 864 ± 225 1121 ± 581 1029 ± 499  865 ± 226 888 ± 339 894 ± 234 
 Day 7 886 ± 261 827 ± 210 1088 ± 326   a 1032 ± 339 837 ± 214 890 ± 314 881 ± 203 
NEAA Admission 1268 ± 317 1242 ± 279 1501 ± 513 1353 ± 324 1253 ± 316 1244 ± 296 1293 ± 339 
 Day 3 1196 ± 338 1163 ± 291 1486 ± 549 1343 ± 432 1169 ± 314 1232 ± 357 1162 ± 319 
 Day 7 1337 ± 383 1241 ± 261 1667 ± 550     a 1618 ± 457 1243 ± 311 a 1374 ± 392 1299 ± 381 
Sum Admission 2079 ± 518 2033 ± 447 2485 ± 876   a 2208 ± 572 2056 ± 508 2019 ± 451 2137 ± 575 
 Day 3 2081 ± 593 2020 ± 485 2607 ± 1080 a 2372 ± 910 2028 ± 506 a 2120 ± 662 2044 ± 525 
 Day 7 2223 ± 585 2068 ± 424 2755 ± 764   a 2650 ± 691 2080 ± 478 a 2265 ± 630 2180 ± 550 
 
CIT: conventional insulin therapy, IIT: intensive insulin therapy, BCAA: branched-chain amino acids, EAA: essential amino acids, NEAA: non-essential 
amino acids. a p ≤ 0.05 in unpaired t-test or Mann-Whitney U on the respective day for survivors versus non-survivors, neonates versus children older than 4 
weeks, or CIT versus IIT.  
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